The findings on the dataset partially support our conclusions and also suggest that a more comprehensive revelation of the specific mechanism of action of VASH2 in pediatric medulloblastoma in the future will require us to not only increase the sample size, but also to carry out studies in vivo, in vitro, and from medulloblastomas with different molecular typing. The gene discussed is VASH2; the disease is medulloblastoma.